Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?  

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, non-metastatic patients?



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Northeast Alabama Regional Medical Center
Howard (feel free not to answer this, as I would i...
Radiation Oncologist at Cedars-Sinai Medical Center
The one-sided p-value was pragmatic (sample size) ...
Medical Oncologist at Oncology Institute of Hope and Innovation
Howard, Would you provide the same guidance for ...
Radiation Oncologist at Cedars-Sinai Medical Center
I assume that the risk of docetaxel varies with ag...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice